
TCBP
Healthcare · Biotechnology · $256,496 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 28, 2024 | Time not confirmed | — | -121.13 | — |
| May 29, 2024 | Time not confirmed | — | -447.21 | — |
| Mar 2, 2022 | Time not confirmed | — | -9.37 | — |
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as…